Drugs / Sabin Strain Inactivated Poliovirus Vaccine
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 31 trial | ||||||
| Phase 3 | NCT05850364 | May 2023 → Feb 2025 | poliomyelitis | Sinovac Biotech Co., Ltd | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT04618783 | Jul → Dec 2019 | poliomyelitis | Sinovac Biotech Co., Ltd | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sabin strain inactivated poliovirus vaccine | “an Sabin strain inactivated poliovirus vaccine (sIPV) manufactured by Sinovac Biotech Ltd., Beijing China” NCT04618783 ↗ |
| Known as | sIPV | “This study is designed to study the immunogenicity and safety of sIPV co-administered with other routine infant vaccines.” NCT05850364 ↗1“an Sabin strain inactivated poliovirus vaccine (sIPV) manufactured by Sinovac Biotech Ltd., Beijing China” NCT04618783 ↗ |
| Modality | Vaccine | “an Sabin strain inactivated poliovirus vaccine (sIPV) manufactured by Sinovac Biotech Ltd., Beijing China” NCT04618783 ↗ |